Seroatlas · Human Serome Atlas

CRELD2

Protein disulfide isomerase CRELD2

Also known as: CREL2_HUMAN, MGC11256

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UXH1
Gene: CRELD2
Ensembl: ENSG00000184164
Chromosome: 22
Canonical length: 353 aa
Protein class: Enzymes, Predicted intracellular proteins
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Predicted to enable calcium ion binding activity and protein disulfide isomerase activity. Predicted to be located in Golgi apparatus; endoplasmic reticulum; and extracellular space. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

353 residues, UniProt reviewed canonical sequence.

>Q6UXH1|CRELD2
     1  MRLPRRAALG LLPLLLLLPP APEAAKKPTP CHRCRGLVDK FNQGMVDTAK KNFGGGNTAW
    61  EEKTLSKYES SEIRLLEILE GLCESSDFEC NQMLEAQEEH LEAWWLQLKS EYPDLFEWFC
   121  VKTLKVCCSP GTYGPDCLAC QGGSQRPCSG NGHCSGDGSR QGDGSCRCHM GYQGPLCTDC
   181  MDGYFSSLRN ETHSICTACD ESCKTCSGLT NRDCGECEVG WVLDEGACVD VDECAAEPPP
   241  CSAAQFCKNA NGSYTCEECD SSCVGCTGEG PGNCKECISG YAREHGQCAD VDECSLAEKT
   301  CVRKNENCYN TPGSYVCVCP DGFEETEDAC VPPAEAEATE GESPTQLPSR EDL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CRELD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.39
Highest tissue expression: 115 nTPM

Expression across tissuesHPA

Tissue

pancreas: 115 nTPM
liver: 87 nTPM
thyroid gland: 61 nTPM
pituitary gland: 59 nTPM
stomach: 42 nTPM
testis: 40 nTPM

Single-cell type

plasma cells: 364 nCPM
epididymal principal cells: 329 nCPM
pancreatic acinar cells: 155 nCPM
extravillous trophoblasts: 154 nCPM
early primary spermatocytes: 153 nCPM
differentiating spermatogonia: 132 nCPM

Immune cell

plasmacytoid DC: 52 nTPM
NK-cell: 36 nTPM
basophil: 34 nTPM
memory B-cell: 29 nTPM
naive B-cell: 28 nTPM
memory CD8 T-cell: 23 nTPM

Brain region

thalamus: 33 nTPM
hypothalamus: 26 nTPM
medulla oblongata: 26 nTPM
pons: 25 nTPM
white matter: 24 nTPM
basal ganglia: 22 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.05
gnomAD pLI: 0
gnomAD missense Z: 0.42
DepMap mean gene effect: 0.04
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CRELD2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CRELD2 as an antibody target. Whether an autoantibody or antibody against CRELD2 could matter depends on whether native CRELD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CRELD2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CRELD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...